India · Delayed Price · Currency is INR Marksans Pharma Statistics
Total Valuation
Marksans Pharma has a market cap or net worth of INR 120.97 billion. The enterprise value is 114.80 billion.
| Market Cap | 120.97B |
| Enterprise Value | 114.80B |
Important Dates
The next estimated earnings date is Monday, August 10, 2026.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | Aug 20, 2026 |
Share Statistics
| Current Share Class | 453.16M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.02% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 43.87% |
| Owned by Institutions (%) | 12.51% |
| Float | 214.42M |
Valuation Ratios
The trailing PE ratio is 28.95 and the forward PE ratio is 22.50.
| PE Ratio | 28.95 |
| Forward PE | 22.50 |
| PS Ratio | 4.10 |
| PB Ratio | 3.96 |
| P/TBV Ratio | 4.23 |
| P/FCF Ratio | 36.93 |
| P/OCF Ratio | 26.41 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 19.11, with an EV/FCF ratio of 35.04.
| EV / Earnings | 27.47 |
| EV / Sales | 3.89 |
| EV / EBITDA | 19.11 |
| EV / EBIT | 22.86 |
| EV / FCF | 35.04 |
Financial Position
The company has a current ratio of 5.17, with a Debt / Equity ratio of 0.11.
| Current Ratio | 5.17 |
| Quick Ratio | 3.12 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 0.57 |
| Debt / FCF | 1.05 |
| Interest Coverage | 20.81 |
Financial Efficiency
Return on equity (ROE) is 15.16% and return on invested capital (ROIC) is 15.73%.
| Return on Equity (ROE) | 15.16% |
| Return on Assets (ROA) | 8.84% |
| Return on Invested Capital (ROIC) | 15.73% |
| Return on Capital Employed (ROCE) | 15.06% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | 16.04M |
| Profits Per Employee | 2.27M |
| Employee Count | 1,840 |
| Asset Turnover | 0.83 |
| Inventory Turnover | 1.41 |
Taxes
In the past 12 months, Marksans Pharma has paid 1.40 billion in taxes.
| Income Tax | 1.40B |
| Effective Tax Rate | 25.06% |
Stock Price Statistics
The stock price has increased by +4.46% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +4.46% |
| 50-Day Moving Average | 245.98 |
| 200-Day Moving Average | 195.48 |
| Relative Strength Index (RSI) | 55.27 |
| Average Volume (20 Days) | 159,357 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Marksans Pharma had revenue of INR 29.51 billion and earned 4.18 billion in profits. Earnings per share was 9.22.
| Revenue | 29.51B |
| Gross Profit | 16.74B |
| Operating Income | 5.02B |
| Pretax Income | 5.61B |
| Net Income | 4.18B |
| EBITDA | 6.01B |
| EBIT | 5.02B |
| Earnings Per Share (EPS) | 9.22 |
Balance Sheet
The company has 9.90 billion in cash and 3.43 billion in debt, with a net cash position of 6.46 billion.
| Cash & Cash Equivalents | 9.90B |
| Total Debt | 3.43B |
| Net Cash | 6.46B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 30.53B |
| Book Value Per Share | 66.74 |
| Working Capital | 21.96B |
Cash Flow
In the last 12 months, operating cash flow was 4.58 billion and capital expenditures -1.31 billion, giving a free cash flow of 3.28 billion.
| Operating Cash Flow | 4.58B |
| Capital Expenditures | -1.31B |
| Depreciation & Amortization | 986.32M |
| Net Borrowing | -318.90M |
| Free Cash Flow | 3.28B |
| FCF Per Share | n/a |
Margins
Gross margin is 56.72%, with operating and profit margins of 17.02% and 14.16%.
| Gross Margin | 56.72% |
| Operating Margin | 17.02% |
| Pretax Margin | 19.00% |
| Profit Margin | 14.16% |
| EBITDA Margin | 20.36% |
| EBIT Margin | 17.02% |
| FCF Margin | 11.10% |
Dividends & Yields
This stock pays an annual dividend of 0.90, which amounts to a dividend yield of 0.34%.
| Dividend Per Share | 0.90 |
| Dividend Yield | 0.34% |
| Dividend Growth (YoY) | 12.50% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 8.68% |
| Buyback Yield | -0.02% |
| Shareholder Yield | 0.32% |
| Earnings Yield | 3.45% |
| FCF Yield | 2.71% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Marksans Pharma is 266.00, which is -0.32% lower than the current price. The consensus rating is "Strong Buy".
| Price Target | 266.00 |
| Price Target Difference | -0.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (3Y) | 15.78% |
| EPS Growth Forecast (3Y) | 22.62% |
Stock Splits
The last stock split was on March 11, 2008. It was a forward split with a ratio of 10.
| Last Split Date | Mar 11, 2008 |
| Split Type | Forward |
| Split Ratio | 10 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |